Related Experiment Video
Updated: Aug 7, 2026
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma
1Department of Pediatrics, University of Texas, MD Anderson Cancer Center, Unit 87, 1515 Holcombe Blvd., Houston, TX 77030-4009, USA. pmanders@mdanderson.org
Abstract:
Liposomal muramyl tripeptide phosphatidyl ethanolamine (L-MTP-PE) is a synthetic biological investigational agent used for treating osteosarcoma. It has been used in both canine and human osteosarcoma to reduce pulmonary metastases, the most common pattern of treatment failure for sarcomas. L-MTP-PE has been well tolerated using the concept of biological cancer therapy during chemotherapy. The use of L-MTP-PE with ifosfamide is the best studied combination with single agent chemotherapy. This may represent a new treatment choice for osteosarcoma patients receiving ifosfamide. Such patients include those with a poor initial histological response to primary therapy and/or metastatic disease including pulmonary metastases. Reduction of side effects of L-MTP-PE, such as fever and/or flu-like symptoms, with ibuprofen has not reduced efficacy. Since improved symptom control is possible using drug combinations that are especially effective for delayed nausea, outpatient high-dose ifosfamide chemotherapy combined with L-MTP-PE may lead to a safe and effective therapy while maintaining the patients' quality of life.
Insights
Liposomal muramyl tripeptide phosphatidyl ethanolamine (L-MTP-PE) shows promise in treating osteosarcoma by reducing lung metastases. Combining L-MTP-PE with ifosfamide chemotherapy may offer a safe and effective treatment option for patients.
Area of Science:
- Oncology
- Immunotherapy
- Pharmacology
Background:
- Osteosarcoma frequently metastasizes to the lungs, representing a major cause of treatment failure.
- Liposomal muramyl tripeptide phosphatidyl ethanolamine (L-MTP-PE) is an investigational biological agent explored for its anti-cancer properties.
- Biological cancer therapy concepts are being integrated with conventional chemotherapy for improved outcomes.
Purpose of the Study:
- To evaluate the efficacy and tolerability of L-MTP-PE in treating osteosarcoma, particularly in reducing pulmonary metastases.
- To assess the combination therapy of L-MTP-PE with ifosfamide chemotherapy.
- To determine if L-MTP-PE can be safely administered alongside chemotherapy, improving patient quality of life.
Main Methods:
- Review of existing studies on L-MTP-PE in canine and human osteosarcoma.
- Analysis of combination therapy data, specifically L-MTP-PE with ifosfamide.
- Evaluation of side effect management, including the use of ibuprofen for L-MTP-PE-associated symptoms.
Main Results:
- L-MTP-PE has demonstrated efficacy in reducing pulmonary metastases in osteosarcoma.
- The combination of L-MTP-PE with ifosfamide is the most studied single-agent chemotherapy combination.
- Side effects like fever and flu-like symptoms associated with L-MTP-PE can be managed with ibuprofen without compromising efficacy.
Conclusions:
- L-MTP-PE, particularly in combination with ifosfamide, presents a potential new therapeutic option for osteosarcoma patients.
- This combination may be beneficial for patients with poor histological response or metastatic disease.
- Outpatient high-dose ifosfamide chemotherapy combined with L-MTP-PE could offer a safe and effective treatment, enhancing patient quality of life through improved symptom management.
